Biopure Headquarters & Office Locations

Biopure (Nasdaq (NASDAQ): BPUR) is headquartered in Cambridge, Massachusetts, United States. Founded in 1984, the company operates across 3 countries with approximately 100 employees worldwide.

Where is Biopure's main office?

Biopure's main headquarters office is located at 11 Hurley Street, Cambridge, Massachusetts 02141-2110. This serves as the company's primary corporate address and is home to its executive leadership team.

Biopure regional offices

Beyond its headquarters in Cambridge, Biopure maintains 6 offices across 3 countries. Regional offices span 3 countries.

Biopure contact information

The main switchboard for Biopure headquarters can be reached at 6172346500. For investor relations, visit biopure.com/investor-relations.

What does Biopure do?

Biopure Corporation was a biopharmaceutical company that specialized in oxygen therapeutics (blood substitutes) for both human and veterinary use. The company developed, manufactured, and marketed oxygen therapeutics, designed to transport oxygen to the body's tissues. The oxygen technology uses hemoglobin-based oxygen carrying molecules in solution (HBOCs) to increase oxygen transfer to the tissues. The competing companies with Biopure were Allied Pharmaceutical, Northfield Laboratories, Baxter International and Hemosol of Toronto. The company developed two products: Hemopure (HBOC-1) [hemoglobin glutamer-250 (bovine)] for human use, and Oxyglobin (HBOC-301) [hemoglobin glutamer-200 (bovine)] for veterinary use. In April 2001, Hemopure was approved for commercial sale in South Africa for treatment of acute anemia in general surgery. It is currently approved there and in Russia. However, Hemopure has not been able to gain approval in the U.K. or the U.S. because of safety and reliability concerns of the European Commission and the U.S. Food and Drug Administration (FDA) respectively. The company formed an agreement with the U.S. Navy to aid in preclinical testing of Hemopure for out-of-hospital treatment of trauma patients in hemorrhagic shock. Oxyglobin is the only oxygen therapeutic approved for treatment of canine anemia in both Europe and the U.S. and has been used in treatment for thousands of cases. Unable to obtain FDA approval for Hemopure to date, Biopure ceased operations in 2009 and its assets were purchased by OPK Biotech LLC in September 2009. On July 16, 2009 Biopure announced it had filed for bankruptcy protection under Chapter 11, Title 11, United States Code and entered into an agreement with OPK Biotech LLC for the sale of substantially all of its assets. It in turn went bankrupt and 'Hemoglobin Oxygen Therapeutics LLC was organized in February 2014 in connection with the acquisition of OPK Biotech.' Through it, Hemopure is still available under FDA’s Expanded access Program (EAP).